Drugs for Movement Disorders Part 4 PDF

\#\#\# Slide 26 - COMT Inhibitors 1\. \*\*What is the primary function of COMT inhibitors in Parkinson's treatment?\*\* \- A) Inhibit the breakdown of acetylcholine \- B) Inhibit the breakdown of dopamine \- C) Inhibit the breakdown of L-Dopa \- D) Inhibit the breakdown of serotonin \*\*Answer...

\#\#\# Slide 26 - COMT Inhibitors 1\. \*\*What is the primary function of COMT inhibitors in Parkinson's treatment?\*\* \- A) Inhibit the breakdown of acetylcholine \- B) Inhibit the breakdown of dopamine \- C) Inhibit the breakdown of L-Dopa \- D) Inhibit the breakdown of serotonin \*\*Answer\*\*: C) Inhibit the breakdown of L-Dopa 2\. \*\*Which of the following is a side effect commonly associated with tolcapone?\*\* \- A) Hepatotoxicity \- B) Cardiovascular toxicity \- C) Nephrotoxicity \- D) Insomnia \*\*Answer\*\*: A) Hepatotoxicity 3\. \*\*What is the effect of COMT inhibitors on motor function in Parkinson's patients?\*\* \- A) They provide immediate relief of symptoms \- B) They help reduce fluctuations in motor function \- C) They eliminate dyskinesias \- D) They only work in advanced stages of Parkinson's \*\*Answer\*\*: B) They help reduce fluctuations in motor function \#\#\# Slide 27 - COMT Inhibitors (continued) 4\. \*\*Which medication combination includes entacapone for simplifying the drug regimen in Parkinson's patients?\*\* \- A) Sinemet® \- B) Stalevo® \- C) Rytary® \- D) Parcopa® \*\*Answer\*\*: B) Stalevo® 5\. \*\*What is the significance of the reddish-brown urine side effect when taking COMT inhibitors?\*\* \- A) It indicates liver toxicity \- B) It is a harmless side effect \- C) It indicates renal failure \- D) It is a sign of drug overdose \*\*Answer\*\*: B) It is a harmless side effect 6\. \*\*COMT inhibitors are most commonly used in combination with which other class of drugs?\*\* \- A) Anticholinergics \- B) MAO-B inhibitors \- C) Levodopa/carbidopa \- D) Beta-blockers \*\*Answer\*\*: C) Levodopa/carbidopa \#\#\# Slide 28 - Adenosine Antagonists 7\. \*\*Which of the following drugs is an adenosine A2A receptor antagonist used to treat Parkinson's disease?\*\* \- A) Istradefylline \- B) Pramipexole \- C) Ropinirole \- D) Amantadine \*\*Answer\*\*: A) Istradefylline 8\. \*\*What is a common side effect associated with adenosine A2A receptor antagonists?\*\* \- A) Dyskinesias \- B) Weight gain \- C) Sedation \- D) Hypotension \*\*Answer\*\*: A) Dyskinesias 9\. \*\*Which of the following best describes the mechanism of action of adenosine A2A receptor antagonists in Parkinson's disease?\*\* \- A) Increase dopamine synthesis \- B) Block adenosine receptors to improve motor function \- C) Inhibit acetylcholine \- D) Block serotonin receptors \*\*Answer\*\*: B) Block adenosine receptors to improve motor function \#\#\# Slide 29 - Amantadine 10\. \*\*Which of the following is an indication for the use of amantadine in Parkinson's disease?\*\* \- A) Early-stage monotherapy \- B) Adjunctive therapy for dyskinesias \- C) Treatment of hallucinations \- D) Treatment of constipation \*\*Answer\*\*: B) Adjunctive therapy for dyskinesias 11\. \*\*Which side effect is unique to amantadine treatment?\*\* \- A) Livedo reticularis \- B) Hepatotoxicity \- C) Rhabdomyolysis \- D) Hyperkalemia \*\*Answer\*\*: A) Livedo reticularis 12\. \*\*Amantadine was initially developed for the treatment of which condition?\*\* \- A) Influenza \- B) Multiple sclerosis \- C) Alzheimer\'s disease \- D) Diabetes \*\*Answer\*\*: A) Influenza \#\#\# Slide 30 - Antimuscarinics 13\. \*\*Which symptom of Parkinson's disease do antimuscarinics primarily target?\*\* \- A) Bradykinesia \- B) Tremor \- C) Postural instability \- D) Akinesia \*\*Answer\*\*: B) Tremor 14\. \*\*Which of the following is a common side effect of antimuscarinics?\*\* \- A) Memory impairment \- B) Hypertension \- C) Bradycardia \- D) Tachypnea \*\*Answer\*\*: A) Memory impairment 15\. \*\*Antimuscarinic drugs like benztropine are less effective than dopaminergic drugs in treating which symptom of Parkinson's disease?\*\* \- A) Tremor \- B) Rigidity \- C) Bradykinesia \- D) Dyskinesia \*\*Answer\*\*: C) Bradykinesia \#\#\# Slide 31 - Dopamine Agonists 16\. \*\*Which dopamine agonist is used as a rescue treatment for "freezing" episodes in Parkinson's disease?\*\* \- A) Apomorphine \- B) Pramipexole \- C) Ropinirole \- D) Rotigotine \*\*Answer\*\*: A) Apomorphine 17\. \*\*Dopamine agonists like pramipexole have which potential side effect?\*\* \- A) Impulse control disorders \- B) Weight gain \- C) Hyperkalemia \- D) Respiratory depression \*\*Answer\*\*: A) Impulse control disorders 18\. \*\*Which dopamine receptor subtype is primarily targeted by ropinirole?\*\* \- A) D1 \- B) D2 \- C) D3 \- D) D4 \*\*Answer\*\*: B) D2 \#\#\# Slide 32 - MAO-B Inhibitors 19\. \*\*Which of the following drugs is an MAO-B inhibitor used in Parkinson's treatment?\*\* \- A) Rasagiline \- B) Bromocriptine \- C) Apomorphine \- D) Entacapone \*\*Answer\*\*: A) Rasagiline 20\. \*\*What is the primary function of MAO-B inhibitors in the treatment of Parkinson's disease?\*\* \- A) Increase dopamine synthesis \- B) Inhibit dopamine breakdown \- C) Block dopamine receptors \- D) Enhance dopamine reuptake \*\*Answer\*\*: B) Inhibit dopamine breakdown 21\. \*\*MAO-B inhibitors like selegiline are contraindicated in combination with which of the following drugs?\*\* \- A) SSRIs \- B) Beta-blockers \- C) Anticholinergics \- D) Calcium channel blockers \*\*Answer\*\*: A) SSRIs \#\#\# Slide 33 - Treatment Strategies 22\. \*\*What is a common strategy to address the \"wearing-off\" effect of levodopa in Parkinson's patients?\*\* \- A) Reduce the dose of levodopa \- B) Add a COMT inhibitor \- C) Discontinue all dopamine agonists \- D) Switch to anticholinergic drugs \*\*Answer\*\*: B) Add a COMT inhibitor 23\. \*\*Which drug class is typically added to levodopa therapy to reduce motor complications in Parkinson's disease?\*\* \- A) Anticholinergics \- B) MAO-B inhibitors \- C) Calcium channel blockers \- D) Beta-blockers \*\*Answer\*\*: B) MAO-B inhibitors 24\. \*\*Which symptom is least likely to improve with dopaminergic therapy in Parkinson's disease?\*\* \- A) Bradykinesia \- B) Tremor \- C) Rigidity \- D) Cognitive impairment \*\*Answer\*\*: D) Cognitive impairment